The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and artificial intelligence, and this momentum is predicted to continue into the 2020s and beyond. Drug development is a costly and time-consuming business, and only a minority of approved drugs generate returns exceeding the research and development costs. As a result, there is a huge drive to make drug discovery cheaper and faster. With modern algorithms and hardware, it is not too surprising that the new technologies of artificial intelligence and other computational simulation tools can help drug developers. In only two years of covid research, many novel molecules have been designed/identified using artificial intelligence methods with astonishing results in terms of time and effectiveness. This paper reviews the most significant research on artificial intelligence in de novo drug design for COVID-19 pharmaceutical research.

Artificial Intelligence Technologies for COVID-19 De Novo Drug Design

Floresta G.;Zagni C.;Gentile D.;Patamia V.;Rescifina A.
2022-01-01

Abstract

The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and artificial intelligence, and this momentum is predicted to continue into the 2020s and beyond. Drug development is a costly and time-consuming business, and only a minority of approved drugs generate returns exceeding the research and development costs. As a result, there is a huge drive to make drug discovery cheaper and faster. With modern algorithms and hardware, it is not too surprising that the new technologies of artificial intelligence and other computational simulation tools can help drug developers. In only two years of covid research, many novel molecules have been designed/identified using artificial intelligence methods with astonishing results in terms of time and effectiveness. This paper reviews the most significant research on artificial intelligence in de novo drug design for COVID-19 pharmaceutical research.
2022
Artificial intelligence
COVID-19
Drug design
Ligand-based drug design
Machine learning
Structure-based drug design
Antiviral Agents
COVID-19
Drug Discovery
Drug Evaluation, Preclinical
High-Throughput Nucleotide Sequencing
Humans
Ligands
SARS-CoV-2
Small Molecule Libraries
Structure-Activity Relationship
Artificial Intelligence
Drug Design
File in questo prodotto:
File Dimensione Formato  
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 381.99 kB
Formato Adobe PDF
381.99 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/528054
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact